Quantum Genomics and Biolab Sanus Pharmaceutical Enter into Exclusive Licensing and Collaboration Agreement for Firibastat in Latin America - Seite 2

About Quantum Genomics

Quantum Genomics is a biopharmaceutical company specializing in the development of a new class of cardiovascular medications based on brain aminopeptidase A inhibition (BAPAI). Quantum Genomics is the only company in the world exploring this innovative approach that directly targets the brain. The company relies on 20 years of academic research from the Paris-Descartes University and the laboratory directed by Dr. Catherine Llorens-Cortes at the Collège de France (French National Institute of Health and Medical Research (INSERM)/ the Scientific Centre for National Research (CNRS)). The goal of Quantum Genomics is to develop innovative treatments for complicated, or even resistant, cases of hypertension (around 30% of patients have poor control of their condition or receive ineffective treatment) and for heart failure (one in two patients diagnosed with severe heart failure dies within five years).

Based in Paris and New York, Quantum Genomics is listed on the Euronext Growth exchange in Paris (FR0011648971- ALQGC) and trades on the OTCQX Best Market in the United States (symbol: QNNTF).

For more information, please visit www.quantum-genomics.com, or follow us on Twitter and LinkedIn

Contact information                                                                                                                    

Quantum Genomics
Jean-Philippe Milon CEO [phone] | [e-mail]	Marc Karako CFO - Investor Relations [phone] | [e-mail]
So Bang (Europe)
Nathalie Boumendil Financial Communications [phone] | [e-mail]	Samuel Beaupain Media Relations and Scientific Communications [phone] | [e-mail]
LifeSci (USA)
Dan Ferry Financial Communications [phone]| [e-mail]	Michael Tattory Media Relations and Scientific Communications [phone] | [e-mail]
Biolab Sanus Pharmaceutical
Cleiton de Castro Marques CEO [phone] | [e-mail]	José Roberto da Costa Pereira Business and Innovation Director [phone] | [e-mail]